If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Jaypirca ® (pirtobrutinib) tablets
50 mg,100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Are there any dose modifications for non-hematologic adverse events?
Dose modifications are recommended for any grade 3 non-hematologic toxicity.
Dose Modifications for Non-Hematologic Adverse Events
Dose modifications are recommended for any grade 3 non-hematologic toxicity.1
Recommended Dose Modifications of Pirtobrutinib for Non-Hematologic Adverse Reactions Based on a Starting Dosage of 200 mg summarizes the recommended dose modifications for hematologic adverse events.
If the following adverse reaction... |
Occurs for the... |
Then... |
And... |
Any grade 3 or greater non-hematologic toxicityb |
first time |
interrupt pirtobrutinib until recovery to grade 1 or baseline |
restart at original dose level (200 mg daily)b. |
second time |
restart at 100 mg daily. |
||
third time |
restart at 50 mg daily. |
||
fourth time |
discontinue pirtobrutinib |
do not restart. |
aAsymptomatic lipase increase may not necessarily warrant dose modification.
bEvaluate the benefit-risk before resuming treatment at the same dose for a grade 4 non-hematological toxicity.
Enclosed Prescribing Information
Reference
1Jaypirca [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
Date of Last Review: December 15, 2022